Georgia IVF Success Rate vs Spain: Age Stratification & Technical Difference Analysis

Comparing Success Rates Between the Two Countries from a Doctor's Perspective: First Look at Age, Then at Data Metrics

In my daily consultations, I am often asked the same question by patients: "Doctor, which has a higher success rate, Georgia or Spain?"

As a reproductive specialist, my answer is usually: Discussing success rates without considering age, etiology, and statistical data metrics has limited reference value. The two countries have different technical systems, patient selection criteria, and data reporting methods. Directly comparing numbers can be misleading. Below, I will break down this comparison from a clinical decision-making perspective.

I. Core Differences in Success Rates Between the Two Countries: Statistical Metrics and Patient Demographics

Success rate data is an important reference for patients choosing a destination, but it is necessary to first understand the statistical logic behind the data.

Doctor's Interpretation: If you only look at the "clinical pregnancy rate," data from some top clinics in Georgia is close to the median level in Spain. However, when converted to "cumulative live birth rate," due to stricter statistical metrics, Spanish data is usually higher. This is not a gap in technology itself, but a "numerical illusion" caused by different statistical methods.

II. Divergence in Success Rates by Age Group: Key Decision-Making Basis

Age is the most critical factor affecting IVF success rates, regardless of nationality. Below is a comparative reference for different age groups based on industry consensus data.

Under 35 Years Old

• Georgia: Clinical pregnancy rate approximately 45%-55%, cumulative live birth rate approximately 50%-60% (up to 65% in some top clinics).
• Spain: Clinical pregnancy rate approximately 50%-60%, cumulative live birth rate approximately 55%-65% (more uniform laboratory standards and embryo culture techniques).
• Doctor's Advice: The difference between the two countries is small in this age group. The choice depends more on cost, legal environment, and waiting time.

35-40 Years Old

• Georgia: Clinical pregnancy rate approximately 35%-45%, cumulative live birth rate approximately 35%-45%.
• Spain: Clinical pregnancy rate approximately 40%-50%, cumulative live birth rate approximately 40%-50% (advantages of PGT-A screening begin to show).
• Doctor's Advice: Spain's blastocyst culture and PGT-A technology are more valuable for embryo selection in advanced age, but the cost is also higher.

40-43 Years Old

• Georgia: Clinical pregnancy rate approximately 15%-25%, cumulative live birth rate approximately 12%-18% (some clinics accept attempts with own eggs, but success rates drop significantly).
• Spain: Clinical pregnancy rate approximately 20%-30%, cumulative live birth rate approximately 18%-25% (earlier recommendation for donor eggs, thus boosting live birth rate data).
• Doctor's Advice: In this age group, a serious discussion about donor egg options is necessary. Spain has advantages in the regulation and safety of the donor egg process.

Over 43 Years Old

• Georgia: Clinical pregnancy rate with own eggs below 10%, cumulative live birth rate below 5%.
• Spain: Most reputable reproductive centers directly recommend using donor eggs; cycles with own eggs require strict evaluation.
• Doctor's Advice: For patients over 43, regardless of the country chosen, priority should be given to donor egg or embryo donation programs to improve efficiency and reduce economic costs.

Practitioner's Observation: I have seen too many patients over 40 attracted by "success rate numbers" while ignoring age-stratified data. The truth is: the live birth rate for autologous IVF in women over 43 is below 10% worldwide. This is not a problem with the country or clinic, but a natural law of egg quality. When choosing a destination, first ask for "data for my age group," not the "average success rate."

III. Why Are There Differences in Technical Approaches Between the Two Countries?

Behind the technical differences lies the combined effect of the legal environment, business logic, and medical traditions.

• Legal Differences: Spain has strict regulations on assisted reproduction. The 2016 revised "Assisted Reproduction Law" clearly defines rules for embryo culture, PGT application, and egg freezing duration. Georgia's legal environment is relatively relaxed, with fewer restrictions on third-party reproduction and gender selection, attracting some patients with special needs, but also leading to uneven laboratory standards.
• Technical Tradition: Spain is one of the birthplaces of reproductive medicine in Europe, with many reproductive centers having over 30 years of history and well-established laboratory technician training systems. Reproductive medicine in Georgia started later, but technology has improved rapidly in recent years through the introduction of international equipment and hiring of overseas experts.
• Business Logic: Medical costs in Georgia are lower. Some clinics attract patients with "low-price strategies," which may lead to reduced laboratory investment and embryo culture time. Costs in Spain are higher, but price transparency is also greater.

IV. The Most Easily Overlooked Detail: Data Tracking Period and Loss to Follow-Up Rate

This point is almost never mentioned by patients during consultations, but it is crucial for judging the authenticity of success rate data.

• Georgia: Some clinics only track the "clinical pregnancy rate at 4 weeks post-transfer" and do not conduct long-term follow-up for subsequent miscarriages, ectopic pregnancies, or fetal abnormalities. The data looks "good," but the actual live birth rate may be 5-10 percentage points lower.
• Spain: Most reputable centers track until 12 weeks of gestation, 24 weeks, or even live birth, making the data closer to the true outcome.
• Doctor's Reminder: During consultations, directly ask three questions: "Is your success rate the clinical pregnancy rate or the live birth rate?" "How many patients are included in the statistical period?" "What is your loss to follow-up rate?" Clinics that can answer these clearly have more credible data.

V. Factors Influencing Cost: Balancing Success Rate and Cost-Effectiveness

Cost is an important consideration for patients making a choice, but it needs to be assessed within the framework of "total cost per live birth."

Correlation Between Cost and Success Rate: The cost per cycle is higher in Spain, but the cumulative live birth rate is also higher. For patients under 35, Georgia offers better cost-effectiveness. For patients over 38, Spain's PGT-A and blastocyst culture technologies may reduce the number of failed cycles, thereby lowering "total expenditure."

Real Case Reference: A 39-year-old patient with AMH 1.2 underwent 2 unsuccessful cycles in Georgia, spending approximately €18,000. She then transferred to Spain, where in 1 cycle, she obtained a transferable embryo through PGT-A screening and achieved a successful live birth, spending a total of €15,000. In terms of "total cost per live birth," Spain was actually cheaper. This is not an isolated case, but it is not a universal rule either. The key is to choose a technical route that matches your individual condition.

VI. Frequently Asked Questions: The 5 Most Common Questions from Patients

1. "Is the success rate in Georgia much lower than in Spain?"
   It is not simply "lower" or "higher." The difference is small for patients under 35; for patients over 38, Spain's technical system has more advantages. The core is to look at age-stratified data.
2. "I am 43 years old with AMH 0.5. Which country offers more hope?"
   The success rate with own eggs is very low in both countries. A donor egg program should be the priority. Spain's donor egg system is more standardized with stricter egg donor screening; Georgia's donor egg costs are lower, but regulation is relatively looser.
3. "Can laboratory conditions in Georgia compare with those in Spain?"
   Some clinics in Georgia have introduced international standard laboratories, but compared to the "overall average level" in Spain, a gap still exists. When choosing, focus on the specific clinic's certification, not the country as a whole.
4. "Are visas and stay duration more complicated for Spain?"
   Spain is part of the Schengen Area. The medical visa process is mature, and a single stay usually requires 14-21 days. Georgia offers visa-free entry for Chinese citizens, with more flexible stay durations. This is a convenience factor to consider.
5. "Which country's doctors are more willing to accept complex cases?"
   Some clinics in Georgia are more accepting of patients with advanced age, diminished ovarian reserve, or repeated failure (business-driven). Reputable centers in Spain tend to "screen patients" to ensure their success rate data is not lowered. This can be both good and bad – you need to judge based on your own situation.

VII. Risk Reminders: Three Questions to Clarify Before Choosing

• Data Verification Risk: Georgia lacks a national assisted reproduction data registration system. Success rates published by some clinics may be "filtered" (only counting patients with a good prognosis). Request data from a "consecutive patient cohort," not "selected cases."
• Legal Protection Risk: Although Georgia's legal environment is relaxed, there is less judicial practice and uncertainty regarding embryo ownership, parentage determination, and dispute resolution. Spain's legal system is more comprehensive, with clearer patient rights protection.
• Follow-up Care Risk: After a successful pregnancy in Georgia, planning for prenatal check-up coordination, medication support, and luteal phase support upon returning home is necessary. Spain's medical records and medication protocols are more aligned with international standards, making the transition smoother.

Observation from 10 Years in Practice: Choosing a country is not about selecting a "success rate number," but finding the intersection of "technical trust + legal security + cost affordability." I have seen cases of success in Georgia on the first try, and cases of failure in Spain after 3 attempts. Individual differences far outweigh average national differences. The professional approach is: first, complete a comprehensive fertility assessment in your home country (AMH, antral follicle count, karyotype, uterine cavity evaluation), then have video consultations with doctors from both countries with your report, and finally make a decision based on your own "priority ranking."

VIII. Suggested Next Steps

• Step 1: Complete a basic fertility assessment (AMH, FSH, LH, antral follicle count, semen analysis, karyotype, infectious disease screening). This is the prerequisite for all decisions.
• Step 2: Clarify your own "priority ranking" – is it success rate priority? Cost priority? Legal protection priority? Or time flexibility priority?
• Step 3: Select 2-3 target clinics (1-2 in Georgia and 1-2 in Spain) and request success rate data that is "age-stratified and specifies the statistical metric."
• Step 4: Schedule video consultations, focusing on the doctor's logic for handling complex cases, rather than promised success rate numbers.
• Step 5: Confirm logistical details such as visa process, stay duration, medical translation, and emergency handling plans.

Assisted reproduction is a process full of variables. No country or clinic can offer a "guarantee of success." The most honest advice I can give as a doctor is: First understand yourself, then choose your destination. Data is a reference, but your age, etiology, and ovarian reserve are the determining factors.